Related Experiment Video
Updated: Jan 23, 2026

Multilevel Microdissection and Functional-Structural Profiling of Human Renal Arterial Branches
Published on: September 5, 2025
The Effects of Dapagliflozin on Systemic and Renal Vascular Function Display an Epigenetic Signature
Anna Solini1, Marta Seghieri2, Livia Giannini2
1Department of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, Italy.
Context:
Mechanisms mediating the cardiovascular and renal protection exerted by SGLT2 inhibitors are still partially unknown. We investigated whether dapagliflozin modulates systemic and renal vascular function and structure, and induces epigenetic modifications.
Subjects And Methods:
Forty hypertensive patients with type 2 diabetes were randomly assigned to 4-week treatment with dapagliflozin 10 mg or hydrochlorothiazide (HCT) 12.5 mg. Routine analyses; plasma renin activity; aldosterone, catecholamine, and 24-hour urinary electrolyte levels; flow-mediated dilation (FMD) of the brachial artery; carotid-femoral pulse-wave velocity (PWV); augmentation index; and resistive index and dynamic renal resistive index (DRIN) were measured at baseline and after treatment. Circulating miRNAs (miRs) related to heart failure (miR30e-5p, miR199a-3p), endothelial dysfunction (miR27b and miR200b), and renal function (miR130b-3p, miR21-5p) were assessed and related to the effects of treatments.
Results:
Dapagliflozin and HCT marginally lowered blood pressure. Fasting glucose was lowered, whereas 24-hour diuresis, glycosuria, and osmolar clearance were increased by dapagliflozin (P < 0.001 for all), without affecting sodium excretion and glomerular filtration rate. Magnesium levels significantly increased after dapagliflozin treatment (P = 0.02). Neither dapagliflozin nor HCT modified FMD or PWV. DRIN did not vary in the dapagliflozin group, whereas it increased in the HCT group (P = 0.047 for time by treatment interaction). Both treatments induced variations in the expression of some miRs; dapagliflozin, but not HCT, significantly up-regulated miR30e-5p and downregulated miR199a-3p.
Conclusion:
A putative epigenetic regulation of the protecting cardiovascular effect exerted by SGLT2 inhibitors was found. Dapagliflozin might exert nephroprotection by preserving renal vasodilating capacity.
Insights
Sodium-glucose cotransporter 2 (SGLT2) inhibitors like dapagliflozin may offer cardiovascular and kidney protection through epigenetic modifications. Dapagliflozin appears to preserve renal vasodilating capacity, contributing to nephroprotection.
Area of Science:
- Cardiovascular research
- Nephrology
- Endocrinology
Background:
- The precise mechanisms behind the cardiovascular and renal protective effects of SGLT2 inhibitors remain incompletely understood.
- Investigating these mechanisms is crucial for optimizing treatment strategies in patients with type 2 diabetes and hypertension.
Purpose of the Study:
- To determine if dapagliflozin influences systemic and renal vascular function and structure.
- To explore whether dapagliflozin induces epigenetic modifications, specifically changes in circulating microRNAs (miRs).
Main Methods:
- A 4-week randomized trial comparing dapagliflozin (10 mg) with hydrochlorothiazide (HCT, 12.5 mg) in 40 hypertensive patients with type 2 diabetes.
- Comprehensive assessments included routine analyses, hormonal levels, urinary electrolytes, flow-mediated dilation (FMD), pulse-wave velocity (PWV), and dynamic renal resistive index (DRIN).
- Circulating miRs associated with heart failure, endothelial dysfunction, and renal function were analyzed.
Main Results:
- Both dapagliflozin and HCT showed modest blood pressure reduction. Dapagliflozin increased diuresis, glycosuria, and osmolar clearance, with a significant rise in magnesium levels, but did not alter sodium excretion or glomerular filtration rate.
- Neither drug affected FMD or PWV. Dapagliflozin preserved DRIN, unlike HCT which increased it. Specific miRs related to heart failure were modulated by dapagliflozin, with up-regulation of miR30e-5p and down-regulation of miR199a-3p.
Conclusions:
- Dapagliflozin may exert cardiovascular protective effects through putative epigenetic regulation.
- The drug appears to offer nephroprotection by maintaining renal vasodilating capacity.
Related Concept Videos
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
Transfer Function in Control Systems
To derive the transfer function, consider a general nth-order linear time-invariant...
Functional Brain Systems: Limbic System
Serum Studies: Renal Function Tests
Seedless Vascular Plants

